Rank |
Status |
Study |
1 |
Unknown †
|
Esomeprazole Treatment for Patients With Lymphocytic Gastritis
Condition: |
Lymphocytic Gastritis |
Intervention: |
Drug: Esomeprazole |
Outcome Measures: |
The primary objective is to assess the healing rate of; patients with lymphocytic Gastritis irrespective of H. pylori status after treatment; with esomeprazole 20 mg twice daily for 2 weeks.; Secondary objective of the study are to evaluate the grade and activity of Gastritis before and after; treatment according to updated Sydney classification, to assess the clinical GI symptoms at baseline and after 3 months; and to evaluate influence of the H. pylori-Status |
|
2 |
Unknown †
|
Study of the Chinese Prescription Weiqi Decoction on Chronic Atrophic Gastritis
Condition: |
Gastritis |
Intervention: |
Drug: Weiqi decotion |
Outcome Measures: |
Symptoms and conditions of tongue and pulse,the gastroscopy and pathological change; Indicates of liver and renal function |
|
3 |
Recruiting
|
A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
Conditions: |
Acute Gastritis; Chronic Gastritis |
Interventions: |
Drug: DA-6034; Drug: Rebamipide 300mg |
Outcome Measures: |
The number of erosions comparing the before and after the administration. For example, if the number of the erosion is 0, the score is 1 (normal).; The number of erosions diagnosed by the gastroscope; The severity of the digestive symptoms (Scale of 1 to 5) |
|
4 |
Not yet recruiting
|
Gastropanel for Gastric Atrophy and Cancer Risk Assessment
Conditions: |
Gastritis, Atrophic; Stomach Neoplasms |
Interventions: |
Procedure: GastroPanel test; Procedure: Gastroscopy |
Outcome Measure: |
Sensitivity and Specificity of the GastroPanel test for the detection of AG |
|
5 |
Unknown †
|
The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy
Conditions: |
Helicobacter Pylori Infection; Peptic Ulcer; Bile Reflux; Gastritis |
Intervention: |
|
Outcome Measure: |
|
|
6 |
Unknown †
|
The Metabolic Contribution of the Human Microbiota to Resting Energy Expenditure
Condition: |
Gastritis |
Intervention: |
Procedure: Resting Energy Expenditure examination |
Outcome Measure: |
|
|
7 |
Recruiting
|
Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
Conditions: |
Helicobacter Pylori Infections; Atrophic Gastritis; Gastric Cancer |
Intervention: |
Drug: Triple therapy |
Outcome Measures: |
Gastric cancer mortality; Gastric cancer incidence; All-cause mortality; Incidence of- and mortality from other medical conditions |
|
8 |
Unknown †
|
Activation and Recruitment of GIL During Hp Infection
Conditions: |
Helicobacter Gastritis; Dyspepsia |
Intervention: |
|
Outcome Measure: |
|
|
9 |
Recruiting
|
Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer
Condition: |
Early Gastric Cancer or Gastric Adenoma |
Interventions: |
Drug: Arm1: Statin; Drug: Arm2: Placebo |
Outcome Measure: |
Proportion of the patients with high-risk (III/IV) OLGA stages |
|
10 |
Not yet recruiting
|
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
Condition: |
Helicobacter Infections |
Interventions: |
Procedure: Gastroscopy; Device: EndoFaster test; Other: Clo test; Other: Faecal Helicobacter pylori antigen |
Outcome Measure: |
Diagnostic accuracy of the EndoFaster test in H. pylori diagnosis |
|
11 |
Recruiting
|
A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer
Conditions: |
Gastric Cancer; Stomach Cancer; Gastrectomy |
Intervention: |
Procedure: Roux-en-Y or Billroth II |
Outcome Measures: |
The aim of this study is to compare Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy for gastric cancer in terms of postoperative outcomes.; Quality of life pre and post operatively will be compared between Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy.; Gastrointestinal symptoms assessment; Assessing nutritional status; Grading of Gastritis and/or esophagitis on endoscopy |
|
12 |
Unknown †
|
Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
Conditions: |
Helicobacter Pylori Infection; Chronic Gastritis |
Interventions: |
Drug: esomeprazole; Drug: moxifloxacin; Drug: amoxicillin |
Outcome Measures: |
Efficacy of a combination of esomeprazole (E), moxifloxacin (M) and amoxicillin (A) for third line therapy of H. pylori infection.; Comparison of EMA 7 days versus EMA 14 days. Hypothesis: superiority of EMA 14 days 4 weeks after end of eradication therapy; Tolerability,safety, post treatment resistance, influence of host genetics (CYP status) and pathogenicity factors of H. pylori on treatment success. |
|
13 |
Unknown †
|
Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
Conditions: |
Helicobacter Infections; Gastritis; Gastric Ulcer; Duodenal Ulcer |
Intervention: |
Drug: rabeprazole, amoxicillin, clarithromycin, metronidazole |
Outcome Measures: |
Which treatment yields the higher re-eradication rate of H. pylori infection; Side effects |
|
14 |
Unknown †
|
Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
Conditions: |
Helicobacter Infections; Gastritis; Gastric Ulcer; Duodenal Ulcer |
Intervention: |
Drug: Lansoprazole, clarithromycin, amoxicillin |
Outcome Measures: |
Whether the tailored treatment yields a higher eradication rate in comparison with the standard treatment; Cost-effectiveness of the tailored strategy |
|
15 |
Recruiting
|
Control of Helicobacter Pylori Infection by Probiotics
Condition: |
Helicobacter Pylori Infection |
Interventions: |
Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475; Other: Placebo |
Outcome Measures: |
to decrease H. pylori gastric load; To decrease dyspeptic symptoms |
|
16 |
Recruiting
|
High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication
Conditions: |
Dyspepsia; Helicobacter-associated Gastritis; Stomach Disorders |
Interventions: |
Drug: Double dose of PPI; Drug: sequence of drug use |
Outcome Measures: |
Eradication rate; Adherence rate/adverse events; Prevalence of clarithromycin resistance HP; Symptomatic responses regarding dyspeptic symptoms after HP eradication |
|
17 |
Recruiting
|
Concomitant Therapy of H. Pylori
Condition: |
Gastritis, Gastric Ulcer, and Duodenal Ulcer |
Intervention: |
Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole |
Outcome Measure: |
Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori |
|
18 |
Recruiting
|
HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome
Condition: |
Atrophic Glossitis, Burning Mouth Syndrome |
Intervention: |
Dietary Supplement: Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic |
Outcome Measures: |
Number of participants with finding the HLA-DRB1 and HLA-DQB1; Number of participants with finding the HLA-DRB1-DQB1 haplotype |
|
19 |
Recruiting
|
Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment
Conditions: |
Coronary Occlusion/Thrombosis; Peptic Ulcer Hemorrhage |
Intervention: |
Other: Screening for risk factors for ulcer bleeding |
Outcome Measures: |
Admission for ulcer bleeding or haemorrhagic Gastritis; Compliance with antithrombotic medicine; Identification of patients with Benefit of Proton pump inhibitor Prophylaxis; Gastrointestinal bleeding; Uncomplicated ulcers; Death; Acute coronary syndrome |
|
20 |
Not yet recruiting
|
Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia
Condition: |
Dyspepsia |
Interventions: |
Drug: Rebamipide; Drug: Placebo (for Esomeprazole); Drug: Esomeprazole |
Outcome Measures: |
Dyspepsia symptoms; quality of life |
|